Suppr超能文献

使用大鼠模型对14C-血管内皮生长因子控释微球进行药代动力学特征研究。

Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model.

作者信息

Kim Tae-Kyoung, Burgess Diane J

机构信息

School of Pharmacy, University of Connecticut, Storrs 06269, USA.

出版信息

J Pharm Pharmacol. 2002 Jul;54(7):897-905. doi: 10.1211/002235702760089009.

Abstract

The objectives of this study were to characterize the pharmacokinetics of vascular endothelial growth factor (VEGF) in poly(lactic-co-glycolic) acid (PLGA) microspheres using a rat model, and to develop a pharmacokinetic model for this controlled release formulation. 14C-VEGF was encapsulated using a solid-in-oil-in-water emulsification method. The microspheres were administered subcutaneously to rats and the pharmacokinetic parameters were compared with those of protein solutions. Intravenous administration of protein solutions resulted in short half-lives and subcutaneous administration resulted in rapid clearance from the subcutaneous tissue, with high plasma concentrations as expressed by rapid absorption and elimination. The subcutaneous administration of the VEGF microspheres produced low plasma concentrations and high subcutaneous concentrations over a period of 7 weeks. The area under the curve (AUC), the time required to achieve the maximum concentration (tmax), the maximum concentration (Cmax) in blood samples and the elimination rate constant (kel) values at the subcutaneous tissue site were selected to compare the pharmacokinetic characterization of VEGF microspheres with that of protein solutions. The in-vivo release profiles of the proteins were slower than the in-vitro release profiles and they followed the same trend as the in-vitro and in-vivo PLGA degradation rates. The PLGA microsphere degradation was the determinant step for VEGF release from the microspheres and its absorption at the subcutaneous site. Microspheres appear to be an attractive system for the localized rate-controlled delivery of VEGF. 14C-Methylation via reductive alkylation of VEGF did not affect its mitogenic activity, however approximately 25% activity was lost following release from PLGA microspheres. This loss of activity may be due to degradation in an acidic environment as a result of PLGA degradation.

摘要

本研究的目的是使用大鼠模型表征血管内皮生长因子(VEGF)在聚乳酸-乙醇酸共聚物(PLGA)微球中的药代动力学,并建立该控释制剂的药代动力学模型。采用水包油包固乳化法包封14C-VEGF。将微球皮下注射给大鼠,并将药代动力学参数与蛋白质溶液的参数进行比较。静脉注射蛋白质溶液导致半衰期短,皮下注射导致从皮下组织快速清除,表现为快速吸收和消除,血浆浓度高。VEGF微球皮下给药在7周内产生低血浆浓度和高皮下浓度。选择曲线下面积(AUC)、达到最大浓度所需时间(tmax)、血样中的最大浓度(Cmax)以及皮下组织部位的消除速率常数(kel)值,以比较VEGF微球与蛋白质溶液的药代动力学特征。蛋白质的体内释放曲线比体外释放曲线慢,且与体外和体内PLGA降解速率遵循相同趋势。PLGA微球降解是VEGF从微球中释放及其在皮下部位吸收的决定性步骤。微球似乎是一种有吸引力的VEGF局部控释系统。通过VEGF的还原烷基化进行的14C甲基化不影响其促有丝分裂活性,然而从PLGA微球释放后约25%的活性丧失。这种活性丧失可能是由于PLGA降解导致酸性环境中的降解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验